Empirical Performance of the Case-Control Method: Lessons for Developing a Risk Identification and Analysis System

被引:21
作者
Madigan, David [1 ,4 ]
Schuemie, Martijn J. [2 ,4 ]
Ryan, Patrick B. [3 ,4 ]
机构
[1] Columbia Univ, Dept Stat, New York, NY 10027 USA
[2] Erasmus Univ, Dept Med Informat, Med Ctr Rotterdam, NL-3000 DR Rotterdam, Netherlands
[3] Janssen Res & Dev LLC, Titusville, NJ USA
[4] Fdn Natl Inst Hlth, Bethesda, MD USA
基金
美国国家卫生研究院;
关键词
SAFETY;
D O I
10.1007/s40264-013-0105-z
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Considerable attention now focuses on the use of large-scale observational healthcare data for understanding drug safety. In this context, analysts utilize a variety of statistical and epidemiological approaches such as case control, cohort, and self-controlled methods. The operating characteristics of these methods are poorly understood. Objective Establish the operating characteristics of the case control method for large scale observational analysis in drug safety. Research Design We empirically evaluated the case control approach in 5 real observational healthcare databases and 6 simulated datasets. We retrospectively studied the predictive accuracy of the method when applied to a collection of 165 positive controls and 234 negative controls across 4 outcomes: acute liver injury, acute myocardial infarction, acute kidney injury, and upper gastrointestinal bleeding. Results In our experiment, the case control method provided weak discrimination between positive and negative controls. Furthermore, the method yielded positively biased estimates and confidence intervals that had poor coverage properties. Conclusions For the four outcomes we examined, the case control method may not be the method of choice for estimating potentially harmful effects of drugs.
引用
收藏
页码:S73 / S82
页数:10
相关论文
共 13 条
[1]  
Agresti A., 2002, CATEGORICAL DATA ANA, DOI [10.1002/0471249688, DOI 10.1002/0471249688]
[2]  
Breslow N. E, 1993, ANAL CASE CONTROL ST, V1
[3]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[4]   Causal inference based on counterfactuals [J].
Höfler M. .
BMC Medical Research Methodology, 5 (1)
[5]   Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen [J].
Makarowski, W ;
Zhao, WW ;
Bevirt, T ;
Recker, DP .
OSTEOARTHRITIS AND CARTILAGE, 2002, 10 (04) :290-296
[6]  
Maldonado G, 2002, INT J EPIDEMIOL, V31, P422, DOI 10.1093/ije/31.2.422
[7]   Desideratum for Evidence Based Epidemiology [J].
Overhage, J. Marc ;
Ryan, Patrick B. ;
Schuemie, Martijn J. ;
Stang, Paul E. .
DRUG SAFETY, 2013, 36 :S5-S14
[8]  
Rothman KJ, 2008, Modern Epidemiology, 3rd Edition
[9]   Evaluating Performance of Risk Identification Methods Through a Large-Scale Simulation of Observational Data [J].
Ryan, Patrick B. ;
Schuemie, Martijn J. .
DRUG SAFETY, 2013, 36 :S171-S180
[10]   Defining a Reference Set to Support Methodological Research in Drug Safety [J].
Ryan, Patrick B. ;
Schuemie, Martijn J. ;
Welebob, Emily ;
Duke, Jon ;
Valentine, Sarah ;
Hartzema, Abraham G. .
DRUG SAFETY, 2013, 36 :S33-S47